๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Antiviral agents for hepatitis B

โœ Scribed by John L. Gerin

Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
266 KB
Volume
14
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Monitoring during and after antiviral th
Monitoring during and after antiviral therapy for hepatitis B
โœ Karin L. Andersson; Raymond T. Chung ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 110 KB

Recent studies suggest that long-term suppression of viral replication is critical to reducing the complications of chronic hepatitis B virus (HBV) infection. Monitoring for continued virological response during and after treatment is essential because current treatment options have limited success

Serum HBeAg quantitation during antivira
Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B
โœ Heijtink, Rudolf A.; Kruining, Johannes; Honkoop, Pieter; Kuhns, Mary C.; Hop, W ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 92 KB ๐Ÿ‘ 2 views

Hepatitis Be antigen (HBeAg) seroconversion is considered the principal short-term goal of antiviral therapy in chronic hepatitis B. To test whether the pre-and per-treatment HBeAg quantitation has a higher predictive value than that of hepatitis B virus DNA (HBV-DNA) quantitation for the outcome of

Side effects of long-term oral antiviral
Side effects of long-term oral antiviral therapy for hepatitis B
โœ Robert J. Fontana ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 414 KB

The aim of this review is to summarize the safety profile of the five approved oral nucleoside analogs used to treat chronic hepatitis B virus (HBV) infection, focusing on both the class adverse effects and those that have been reported with individual agents, as well as their safety in pregnancy. A